Chief Medical Officer, Arcellx @arcellx. Board Member @chordomafdn #ImmunoOncology #chordoma Tweets are my opinions.
Oct 12, 2021 • 8 tweets • 3 min read
I completely understand this take. I respect those who feel this way, but I disagree that autologous CAR T should be the standard for allo CAR T. The standard should be other off the shelf therapeutics. Why? See thread.
Current allogeneic CAR Ts are being evaluated in the context of autologous CAR T already existing. So, at the centers where these studies are conducted, any patient who can get auto CAR T will. What does that lead to?
